Allakos Inc (NASDAQ:ALLK) saw a large increase in short interest during the month of June. As of June 15th, there was short interest totalling 5,137,800 shares, an increase of 6.6% from the May 15th total of 4,819,600 shares. Approximately 32.7% of the shares of the company are short sold. Based on an average daily trading volume, of 284,100 shares, the short-interest ratio is presently 18.1 days.
ALLK traded down $0.19 during trading hours on Friday, hitting $31.58. The company’s stock had a trading volume of 403,742 shares, compared to its average volume of 380,456. Allakos has a fifty-two week low of $29.34 and a fifty-two week high of $65.48. The business’s 50-day moving average is $40.45.
Allakos (NASDAQ:ALLK) last posted its earnings results on Wednesday, May 8th. The company reported ($0.47) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.13). As a group, equities analysts predict that Allakos will post -1.94 EPS for the current fiscal year.
A number of hedge funds and other institutional investors have recently modified their holdings of ALLK. Great West Life Assurance Co. Can bought a new position in Allakos during the 4th quarter valued at $89,000. BNP Paribas Arbitrage SA boosted its stake in Allakos by 4,853.8% during the 1st quarter. BNP Paribas Arbitrage SA now owns 3,220 shares of the company’s stock valued at $130,000 after purchasing an additional 3,155 shares in the last quarter. Amundi Pioneer Asset Management Inc. bought a new position in Allakos during the 1st quarter valued at $142,000. SG Americas Securities LLC bought a new position in Allakos during the 1st quarter valued at $153,000. Finally, Metropolitan Life Insurance Co. NY boosted its stake in Allakos by 203.1% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 2,961 shares of the company’s stock valued at $155,000 after purchasing an additional 1,984 shares in the last quarter. 53.01% of the stock is owned by hedge funds and other institutional investors.
Separately, Zacks Investment Research cut General Finance from a “buy” rating to a “hold” rating in a research report on Monday, July 15th.
Allakos Company Profile
Allakos Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis.
Receive News & Ratings for Allakos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allakos and related companies with MarketBeat.com's FREE daily email newsletter.